First-line therapy will possibly open a substantial market. Epkinly is currently accepted for DLBCL individuals that have actually gotten 2 or even more therapies.
发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/genmab-ceo-points-to-epkinly-data-as-main-event-of-the-year/